Zacho Helle D, Barsi Tamás, Mortensen Jesper C, Bertelsen Henrik, Petersen Lars J
a 1 Department of Nuclear Medicine, Clinical Cancer Research Centre, Aalborg University Hospital , Aalborg, Denmark.
b 2 Department of Clinical Physiology, Viborg Hospital , Viborg, Denmark.
Scand J Urol. 2016;50(1):29-32. doi: 10.3109/21681805.2015.1076031. Epub 2015 Aug 29.
The aim of this study was to evaluate, using international urology and oncology guidelines, the criteria for performing bone scintigraphy (BS) in patients with newly diagnosed prostate cancer in a prospective setting with 2 years of follow-up after prostatectomy.
In a prospective setting, criteria from European and US urology and oncology guidelines were evaluated in 220 unselected patients with BS performed as a routine investigation before radical prostatectomy. A prostate-specific antigen level of 0.1 ng/ml or lower after surgery was considered successful and was used as a measure of true-negative BS.
Overall, 200 out of 220 patients (91%) experienced successful radical prostatectomy at 6 months, with a 2 year success rate of 83%. The proportion of redundant BS ranged from 56% to 89% among the guidelines, whereas the outcome after radical prostatectomy was 93% within 6 months after surgery and 86-89% after 2 years of follow-up, without significant differences among guideline recommendations.
The guidelines from the American Urological Association and the criteria recently published by the present group proposed the largest proportion of redundant BS without compromising patient-related outcome.
